News

01/13/2026 in Company News, Homepage News, News Highlight, RAG-17, Uncategorized

Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS

Nantong, China – January 13, 2026 – Ractigen Therapeutics is pleased to announce that the…
Read More
12/12/2025 in Homepage News, News Highlight

Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy

NANTONG, China, December 12, 2025 – Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA)…
Read More
11/17/2025 in Homepage News, News Highlight

Ractigen Publishes Foundational Paper Detailing Its SCAD Platform for Duplex RNA Delivery to the CNS and Beyond in Molecular Therapy – Nucleic Acids

SUZHOU, China, November 17, 2025 – Ractigen Therapeutics, a clinical-stage biotechnology company, today announced the publication…
Read More
04/09/2025 in Homepage News, News Highlight, RAG-17

Ractigen’s RAG-17 ALS Data Shines at AAN 2025: Earns Top Award, Phase I Advances

Final results from an Investigator-Initiated Trial presented for the first time, demonstrating favorable safety, significant…
Read More